Prices are updated after-hours


Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

symbols : SNYNF    crawled date : 2022 - 03 - 24    save search

Pfizer Notches Breakthrough Status in Race to an RSV Vaccine
Published: 2022-03-24 (Crawled : 15:30) - biospace.com/
SNY | $46.22 0.63% 0.63% 1.7M twitter stocktwits trandingview |
Health Technology
| | O: 0.05% H: 0.0% C: 0.0%

vaccine
Global Roundup: Oryzon Genomics, AEterna Zentaris, CanSino and Telix
Published: 2022-03-24 (Crawled : 13:00) - biospace.com/
SNY | $46.22 0.63% 0.63% 1.7M twitter stocktwits trandingview |
Health Technology
| | O: 0.05% H: 0.0% C: 0.0%


BiondVax signs definitive collaboration agreement for the development of a pipeline of innovative nanosized antibody (NanoAb) therapies
Published: 2022-03-24 (Crawled : 12:00) - biospace.com/
SNY | $46.22 0.63% 0.63% 1.7M twitter stocktwits trandingview |
Health Technology
| | O: 0.05% H: 0.0% C: 0.0%

collaboration antibody therapy
PureTech Appoints Sharon Barber-Lui to Board of Directors & Audit Committee
Published: 2022-03-24 (Crawled : 08:00) - biospace.com/
SYBX | $1.79 1.13% 1.12% 38K twitter stocktwits trandingview |
Health Technology
| | O: 2.44% H: 5.15% C: 0.0%
SNY | $46.22 0.63% 0.63% 1.7M twitter stocktwits trandingview |
Health Technology
| | O: 0.05% H: 0.0% C: 0.0%


Innate Pharma Reports Full Year 2021 Financial Results and Business Update
Published: 2022-03-24 (Crawled : 08:00) - biospace.com/
BNPQY | News 3 d | $34.64 -2.68% 130K twitter stocktwits trandingview |
Finance and Insurance
| | O: -0.98% H: 1.17% C: 0.78%
NVO | $123.9 -0.49% 0.23% 2.9M twitter stocktwits trandingview |
Health Technology
| | O: -1.27% H: 0.98% C: 0.93%
SNY | $46.22 0.63% 0.63% 1.7M twitter stocktwits trandingview |
Health Technology
| | O: 0.05% H: 0.0% C: 0.0%
IPHA | $2.48 3.88% 8.1K twitter stocktwits trandingview |
Health Technology
| | O: 0.0% H: 0.0% C: -3.17%

results pharma
MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa with HiSCR75 as the primary endpoint
Published: 2022-03-24 (Crawled : 08:00) - biospace.com/
SNY | $46.22 0.63% 0.63% 1.7M twitter stocktwits trandingview |
Health Technology
| | O: 0.05% H: 0.0% C: 0.0%

scr75 nanobody phase 2
Gainers vs Losers
49% 51%

Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M twitter stocktwits trandingview |
Wholesale Trade

PXMD | $0.7375 79.09% 44.16% 4.5M twitter stocktwits trandingview |
Health Technology

DYNT | $0.371 -5.12% 43.09% 3.3M twitter stocktwits trandingview |
Health Technology

LGVN P 3 d | $2.94 73.96% 42.52% 57M twitter stocktwits trandingview |

HUBC | $1.94 49.23% 32.99% 73M twitter stocktwits trandingview |
n/a

SPCB | $0.4044 46.52% 31.75% 130M twitter stocktwits trandingview |
Electronic Technology

ONVO | $1.34 32.66% 24.62% 54M twitter stocktwits trandingview |
Health Technology

OMQS | $0.6869 32.1% 24.3% 3.6M twitter stocktwits trandingview |
Professional, Scientific, and T...

SNPO | $10.555 29.67% 22.88% 4M twitter stocktwits trandingview |

AMBI | $3.72 -26.77% 21.77% 9.8K twitter stocktwits trandingview |
n/a


Your saved searches
Save your searches and get alerts when important news are released.